All In Biotech

Drug Trial Radar · NCT05772169

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)

Last checked: Nov 20, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,113

Actual

Start

Mar 31, 2023

Primary completion

Nov 19, 2024

Study completion Dec 18, 2024

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to control T2D despite receiving standard of care therapies.

Conditions

  • Hypercortisolism
  • Diabetes Mellitus, Type 2

Interventions

  • Mifepristone 300 MG [Korlym]Drug

    Mifepristone tablets for once daily oral dosing

  • Placebo for mifepristoneDrug

    Placebo tablets for once daily oral dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Prevalence Phase: Prevalence of HypercortisolismTime frame: Screening
  2. Part 2 Treatment Phase: Effect of Treatment on Hypercortisolism with Abnormal Adrenal CT ScanTime frame: Baseline Day 1 to week 24
  3. Part 2 Treatment Phase: Effect of Treatment on Hypercortisolism without Abnormal Adrenal CT ScanTime frame: Baseline Day 1 to week 24

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Site 407

    Escondido, California

  • Site 379

    Gardena, California

  • Site 378

    Huntington Park, California

  • Site 406

    La Jolla, California

  • Site 373

    Los Angeles, California

  • Site 387

    Tarzana, California

  • Site 375

    Torrance, California

  • Site 444

    Edgewater, Florida

  • Site 015

    Fort Lauderdale, Florida

  • Site 009

    Atlanta, Georgia

  • Site 097

    Atlanta, Georgia

  • Site 046

    Covington, Kentucky

  • Site 061

    Metairie, Louisiana

  • Site 377

    New Orleans, Louisiana

  • Site 205

    New Orleans, Louisiana

  • Site 410

    Baltimore, Maryland

  • Site 394

    Hyattsville, Maryland

  • Site 067

    Boston, Massachusetts

  • Site 074

    Ann Arbor, Michigan

  • Site 371

    Las Vegas, Nevada

  • Site 070

    Albany, New York

  • Site 411

    Smithtown, New York

  • Site 181

    Chapel Hill, North Carolina

  • Site 059

    Wilmington, North Carolina

  • Site 436

    Cincinnati, Ohio

  • Site 042

    Cleveland, Ohio

  • Site 077

    Columbus, Ohio

  • Site 195

    Columbus, Ohio

  • Site 435

    Grants Pass, Oregon

  • Site 049

    Portland, Oregon

  • Site 456

    Cedar Park, Texas

  • Site 370

    Dallas, Texas

  • Site 408

    Lufkin, Texas

  • Site 054

    San Antonio, Texas

  • Site 369

    San Antonio, Texas

  • Site 405

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.